A prospective,open-label study of Anastrozole in post-menopausal women with hormone sensitive advanced breast cancer

Inclusion Criteria

• (1)Patients must be adult (age ≥ 18 years age) post-menopausal* women
• (2)Patients must be diagnosed with advanced breast cancer (histologically or cytological confirmation required) i.e. TNM stage III or IV disease (locally advanced or metastatic breast cancer) or locoregional recurrent disease, not suitable for treatment by local surgery or radiation therapy
• (3)Measurable or evaluable disease
• (4)Patients with ER/PR positive tumour or ER/PR unknown status
• (5)Patients must be suitable for endocrine treatment with anastrozole
• (6)Prior adjuvant chemotherapy or endocrine therapy for early breast cancer is allowed, provided such treatment was completed at least twelve months prior to study enrollment
• (7)Performance status 0-2 (As per WHO Classification)
• (8)Concurrent use of bisphosphonates is permitted.
• (9)Patients must give their written informed consent for participation in the study